A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931)

• ClinicalTrials.gov Identifier: NCT01669746
• Recruitment Status: Completed
• First Posted: August 21, 2012
• Last Update Posted: July 11, 2013
• Sponsor: Aderans Research Institute
• Information provided by (Responsible Party): Aderans Research Institute

Study Description

Brief Summary:

Evaluate the ability of injections of Ji Gami(TM) CN to induce hair growth in male and female subjects with hair loss.

Condition or disease	Intervention/treatment	Phase
Androgenetic Alopecia; Male Pattern Baldness; Female Pattern Baldness	Biological: Autologous cultured mixed population of dermal cells	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 34 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: Single (Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of ex Vivo-cultured, Expanded, Occipital Autologous Dermal and Epidermal Cells, Injected Into the Hair Loss Area of the Scalp of Male and Female Subjects With Alopecia
• Study Start Date: June 2012
• Actual Primary Completion Date: April 2013

Arms and Interventions

Arm	Intervention/treatment
Experimental: Treatment	Biological: Autologous cultured mixed population of dermal cells; A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.

Outcome Measures

Primary Outcome Measures :

1. Change from baseline in hair number [ Time Frame: 24 weeks post-injection ]
2. Change from baseline in hair width [ Time Frame: 24 weeks post-injection ]
3. Time course of any treatment benefit [ Time Frame: 24 week post-injection ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 50 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Male and female volunteers 18-50 years old, inclusive.
• Women of childbearing potential must use an adequate form of contraception during study participation.
• Hair loss consistent with Grade III-Vertex, IV, or V based on the based on the Norwood-Hamilton Scale providing there is bridging of hair in the anterior edge of the vertex circle, or class 1 or class 2 based on the Ludwig scale.
• Able to provide informed consent after risks and benefits of the study have been explained.
• Be willing to undergo all study procedures.
• Ability to communicate effectively with study personnel.
• Have no clinically significant disease or abnormal laboratory evaluations taken at the screening visit.
• Agree to abstain from use of any hair growth affecting oral or topical medication including over the counter and herbal medications, minoxidil, finasteride or dutasteride during the course of this study; also agrees to abstain from shaving the head during the course of the study.

Exclusion Criteria:

• Women who are pregnant or lactating.
• Known sensitivity to DMEM/F-12 or any component of the study material.
• Known hypersensitivity to clindamycin hydrochloride, amphotericin B or streptomycin sulfate.
• Subjects who have used minoxidil or any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 6 months of study screening, or finasteride or dutasteride within 12 months of study screening.
• A history of drug or alcohol abuse within 1 year of study enrollment.
• Participation in any other investigational study within 30 days or six half lives of its biologic activity, whichever is longer, before the scalp excision visit(s), and during the time enrolled in this study.
• Clinically significant medical or psychiatric illness currently or within 30 days of study screening as determined by the investigator.
• Clinically significant symptoms of any acute illness within 30 days prior to excision day.
• Any condition that compromises the ability to understand or comply with study requirements.
• Clinically significant abnormal laboratory parameters.
• A positive result at screening for human immunodeficiency virus (HIV 1 or 2), Hepatitis B or C, HTLV I/II.
• Clinically significant dermatologic condition in donation or study zones.
• Prior surgery in the donor or study zones.
• Insufficient hair or scarring in the donor area that might impact cell growth.
• Any disease or condition (medical or surgical) that, in the opinion of the investigator, might compromise hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system function; or any condition that would place the subject at increased risk.

Contacts and Locations

Locations

United States, Arizona

Radiant Research, Inc.

Tucson, Arizona, United States, 85710

United States, California

Radiant Research, Inc.

Santa Rosa, California, United States, 95405

United States, Colorado

Radiant Research, Inc.

Denver, Colorado, United States, 80239

United States, Florida

Radiant Research, Inc.

Pinellas Park, Florida, United States, 33781

United States, Ohio

Radiant Research, Inc.

Akron, Ohio, United States, 44311

United States, South Carolina

Radiant Research, Inc.

Greer, South Carolina, United States, 29650

United States, Texas

Radiant Research, Inc.

San Antonio, Texas, United States, 78229

Sponsors and Collaborators

Aderans Research Institute

More Information

• Responsible Party: Aderans Research Institute
• ClinicalTrials.gov Identifier: NCT01669746
• Other Study ID Numbers: CA-0006931
• First Posted: August 21, 2012
• Last Update Posted: July 11, 2013
• Last Verified: July 2013

Keywords provided by Aderans Research Institute:

Androgenetic Alopecia; Male Pattern Baldness; Female Pattern Baldness; Hair Loss; Baldness

Additional relevant MeSH terms:

Alopecia; Alopecia Areata; Hypotrichosis; Hair Diseases; Skin Diseases; Pathological Conditions, Anatomical